版本:
中国

BRIEF-Aevi Genomic Medicine provides top-line results from saga trial

March 20 Aevi Genomic Medicine Inc:

* Aevi Genomic Medicine provides top-line results from the saga trial of aevi-001

* Aevi Genomic Medicine Inc - trial did not meet primary endpoint

* Aevi Genomic Medicine Inc - trial was well tolerated with no serious adverse events

* Aevi Genomic Medicine Inc - safety analysis demonstrated that aevi-001 was well tolerated at all doses

* Aevi Genomic Medicine- moving forward plan to explore higher doses, refined genomic biomarker,study pediatric patients which should enhance response rates,effect size of aevi-001 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐